Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Prelude Therapeutics, Inc.

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics Announces $25 Million Private Placement
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics Announces Pricing of Public Offering
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics Announces Launch of Proposed Public Offering
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Tickers PRLD
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.